Affordable Access

deepdyve-link
Publisher Website

Placental serotonin systems in pregnancy metabolic complications associated with maternal obesity and gestational diabetes mellitus.

Authors
  • Murthi, Padma1
  • Vaillancourt, Cathy2
  • 1 Department of Medicine, School of Clinical Sciences, Department of Physiology, Monash University, Clayton, Victoria, Australia; Hudson Institute of Medical Research, The Ritchie Centre, Clayton, Victoria, Australia; Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia. Electronic address: [email protected] , (Australia)
  • 2 INRS-Institut Armand-Frappier, Université du Québec and Biomed Research Center, 531 Boulevard des Prairies, Laval, QC H7V 1B7, Canada; Center for Interdisciplinary Research on Well-Being, Health, Society and Environment, Université du Québec à Montréal, Montréal, QC H3C 3P8, Canada. , (Canada)
Type
Published Article
Journal
Biochimica et biophysica acta. Molecular basis of disease
Publication Date
Feb 01, 2020
Volume
1866
Issue
2
Pages
165391–165391
Identifiers
DOI: 10.1016/j.bbadis.2019.01.017
PMID: 30738809
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) regulates diverse physiological and behavioural and processes, also acts as a developmental signal in early embryogenesis and in regulation of fetal development. A number of studies have implicated the prominent role of serotonin transporter (SERT or 5-HTT) and 5-HT receptor subtypes in placental development and function. Here, in this article we have provided a comprehensive review on the important role of 5-HT homeostasis in pregnancy outcomes. More specifically, we have summarised the findings from experimental and clinical studies, the influence of maternal and placental inflammation associated with the gestational diabetes and obesity on placental serotonin synthesis, expression of SERT and 5-HT receptors and their activity. Understanding the molecular regulation of placental SERT and 5-HT receptors using selective pharmacological agonists or antagonists may identify the therapeutic potential of serotonin pathway to improve long-term health outcomes of mothers and her infants exposed to GDM and obesity. Copyright © 2019. Published by Elsevier B.V.

Report this publication

Statistics

Seen <100 times